Genovis AB. (5/16/19). "Press Release: Genovis Signs Distribution Agreement with Fujifilm Wako Pure Chemical for Japan, Taiwan and Singapore Markets".

	Region	Japan
	Organisation	Genovis AB
	Group	Genovis (Group)
	Organisation 2	Fujifilm Wako Pure Chemical Industries Ltd.
	Group	Fujifilm (Group)
	Product	SmartEnzymes™
	Product 2	reagents (bio/biochemical)
	Index term	Fujifilm–Genovis: enzymes, 201905– collab distribution of SmartEnzymes in Japan + Taiwan + Singapore by Fujifilm Wako Pure Chemical
	Person	Olsson, Fredrik (Genovis 201906 CEO)
	Person 2	Ito, Hiroyuki (Fufifilm 201905 General Manager Life Science Development Operations at FF Wako Pure Chemical)

Genovis has entered into a distribution agreement with FUJIFILM Wako Pure Chemical for the Japan, Taiwan and Singapore markets. The agreement includes distribution of current and future Genovis SmartEnzymes™ and will enable Genovis to market and sell products to more scientists in the region.

FUJIFILM Wako Pure Chemical is well established in these markets, with more than 1500 employees involved in the production and distribution of laboratory chemicals, specialty chemicals and clinical diagnostic reagents. Using the local languages, a dedicated team of specialists from FUJIFILM Wako Pure Chemical will distribute and market Genovis’ products. Genovis SmartEnzymes are a good fit with the products offered by FUJIFILM Wako Pure Chemical, which has well-developed sales channels to research and analytical development departments at top biopharmaceutical companies.

“By collaborating with FUJIFILM Wako Pure Chemical, we gain an experienced partner with an established presence as a supplier to the biopharma industry. The company is extremely familiar with the enzymatic reagent market for research, development and quality control. Given its aspirations as a contract manufacturing organization, we see excellent opportunities to build a fruitful and long-lasting partnership with FUJIFILM Wako Pure Chemical.” says Fredrik Olsson, CEO, Genovis.

FUJIFILM Wako Pure Chemical develops and produces high-quality reagents to address the needs of its customers. The company has a longstanding, mature network of dealers and representatives serving pharma and biopharma industry customers in Japan. In addition, FUJIFILM Wako Pure Chemical has local representatives covering the and Taiwan and Singapore markets, where Genovis’ products will now also be represented.

“The biopharmaceutical market is growing in Japan, especially the antibody-based drugs. Genovis offers unique and useful products for antibody drug development that meet customer needs. Our collaboration with Genovis to promote their products in our sales network in Japan, Taiwan and Singapore will lead to successful business growth for both companies,” says Hiroyuki Ito, General Manager, Life Science Development Operations.

For more information, please contact:
Fredrik Olsson, CEO, Genovis AB
T: +46 (0)46-12 12 33
E: [email protected]

ABOUT FUJIFILM Wako Pure Chemical

FUJIFILM Wako Pure Chemical develops and produces high-quality reagents to address research needs in cutting-edge fields, with extensive business in the fields of Specialty Chemicals and Clinical Diagnostics Reagents, as well as Laboratory Chemicals. Based on the corporate philosophy “With commitment to the future of science, the company is dedicated to create the source of happiness for all people”, FUJIFILM Wako Pure Chemical will contribute to development in the fields of academic research, industry and medicine.

ABOUT GENOVIS

Genovis’ business concept is to apply its knowledge and imagination to design and provide innovative tools for development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymesÔ all over the world in innovative product formats that facilitate development and quality control of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on NASDAQ First North Stockholm and Erik Penser Bank is the Company’s Certified Adviser, [email protected], tel: +46 (0)8-463 83 00.

Record changed: 2023-06-05